MedWatch

Biotech firm Resother is well on the way to clinical trials - lands DKK 16 million

Resother Pharma, which is developing a new type of anti-inflammatory medicine, has secured DKK 16 million (USD 2.4 million) - enough to take the company's first drug to clinical trials.

Lone Veng, CEO of Resother Pharma | Foto: Photo: Resother Pharma

Biotech company Resother Pharma will be testing its first medicine on humans soon, after the company has received a million-kroner investment that can see the company though to clinical trials.

Resother Pharma received a total of DKK 16 million (USD 2.4 million) which has come from private investors, Innovationsfonden, the EU program Horizon 2020 and the British charity fund Barts Charity.

Læs hele artiklen

Få 14 dages fri adgang.

Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier